Article
Public, Environmental & Occupational Health
Mohammed Alsuhaibani, Alanoud Aljarbou, Sahar Althawadi, Abdulrahman Alsweed, Sami Al-Hajjar
Summary: S. maltophilia bacteremia is a severe infection with high mortality rates among hospitalized children, especially when associated with risk factors like ICU admission and neutropenia. Susceptibility testing shows trimethoprim and sulfamethoxazole (TMP/SMX) and levofloxacin as effective treatment options.
ANTIMICROBIAL RESISTANCE AND INFECTION CONTROL
(2021)
Article
Infectious Diseases
Maxwell J. Lasko, Jennifer L. Tabor-Rennie, David P. Nicolau, Joseph L. Kuti
Summary: This study investigated the pharmacodynamics of trimethoprim/sulfamethoxazole against susceptible S. maltophilia strains using an in vitro chemostat model. The results showed that even at higher doses, trimethoprim/sulfamethoxazole monotherapy had limited activity against susceptible S. maltophilia.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
(2022)
Article
Microbiology
Vidmantas Petraitis, Ruta Petraitiene, Povilas Kavaliauskas, Ethan Naing, Andrew Garcia, Naoki Ishibashi, Benjamin Georgiades, Roger Echols, Robert A. Bonomo, Yoshinori Yamano, Michael J. Satlin, Thomas J. Walsha
Summary: Cefiderocol demonstrates high efficacy in the treatment of S. maltophilia pneumonia, leading to improved survival rate, reduced bacterial burden, and lung injury in a rabbit model.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2022)
Article
Infectious Diseases
Shauna Jacobson Junco, Mary Catherine Bowman, R. Brigg Turner
Summary: This study examined the clinical outcomes of patients receiving monotherapy for Stenotrophomonas maltophilia infection with different agents. It was found that receiving minocycline, not a fluoroquinolone, was associated with lower mortality compared with TMP/SMX, suggesting that TMP/SMX may not be the treatment of choice for these infections.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
(2021)
Article
Microbiology
Rio Nakamura, Merime Oota, Shuhei Matsumoto, Takafumi Sato, Yoshinori Yamano
Summary: Cefiderocol is a novel antibiotic that shows potent activity against difficult-to-treat Gram-negative bacteria, including strains resistant to carbapenems. In in vitro and animal studies, Cefiderocol demonstrated strong antimicrobial activity against Stenotrophomonas maltophilia, even against strains resistant to trimethoprim-sulfamethoxazole. These results suggest that Cefiderocol could be a promising treatment option for infections caused by S. maltophilia, especially those resistant to traditional antibiotics.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2021)
Article
Immunology
Rui-Xin Wu, Ching-Mei Yu, Sung-Teng Hsu, Ching Hsun Wang
Summary: The emergence of concurrent levofloxacin- and trimethoprim/sulfamethoxazole-resistant Stenotrophomonas maltophilia (LTSRSM) in Taiwan is becoming a serious problem, but clinical data analysis on this has not been reported. A matched case-control-control study was conducted to investigate risk factors for LTSRSM occurrence in hospitalized patients.
JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION
(2022)
Review
Infectious Diseases
Alberto Enrico Maraolo, Federica Licciardi, Ivan Gentile, Annalisa Saracino, Alessandra Belati, Davide Fiore Bavaro
Summary: A systematic review was conducted to evaluate the best treatment for Stenotrophomonas maltophilia (SM) infections. The study found that fluoroquinolones (FQs) and possibly tetracycline derivatives (TDs) may be reasonable alternatives to trimethoprim/sulfamethoxazole (TMP/SMX). More clinical trial data is needed to inform therapeutic choices.
Article
Infectious Diseases
Bruce M. Jones, Jamie L. Wagner, Daniel B. Chastain, P. Brandon Bookstaver, Kayla Stover, Jason Lin, Hannah Matson, Noah White, Madalyn Motesh, Christopher M. Bland
Summary: This study aimed to evaluate risk factors associated with non-susceptible isolates of Stenotrophomonas maltophilia and found that isolation from urine culture was associated with non-susceptibility, while mechanical ventilation and intensive care unit admission were associated with susceptibility. Non-susceptibility to commonly used antimicrobial agents was observed in approximately 50% of isolates. Further research is needed to identify risk factors for non-susceptible isolates.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE
(2022)
Review
Immunology
Ravina Kullar, Eric Wenzler, Jose Alexander, Ellie J. C. Goldstein
Summary: Stenotrophomonas maltophilia is an underappreciated source of morbidity and mortality among gram-negative pathogens, with limited effective treatment options available. The lack of data and supporting evidence for various treatment options is a significant challenge.
OPEN FORUM INFECTIOUS DISEASES
(2022)
Article
Microbiology
Paulina Paprocka, Angelika Mankowska, Karol Sklodowski, Grzegorz Krol, Tomasz Wollny, Agata Lesiak, Katarzyna Gluszek, Paul B. Savage, Bonita Durnas, Robert Bucki
Summary: This study found that ceragenins exhibit strong antibacterial activity against S. maltophilia strains, including inhibition of biofilm formation. Additionally, a synergistic effect was observed when ceragenins were used in combination with conventional antibiotics.
Article
Infectious Diseases
ChengCheng Yue, WeiHua Shen, LiFen Hu, YanYan Liu, YaHong Zheng, Ying Ye, Yuhao Zhang, JiaBin Li
Summary: The study demonstrated that the combination of azithromycin and tigecycline effectively inhibited biofilm formation by S. maltophilia. Specifically, the combination of 2x MIC azithromycin with 1x MIC tigecycline showed the best inhibitory effect, significantly reducing biofilm thickness.
INFECTION AND DRUG RESISTANCE
(2021)
Review
Pharmacology & Pharmacy
Ashlan J. Kunz Coyne, Shelbye Herbin, Kaylee Caniff, Michael J. Rybak
Summary: Stenotrophomonas maltophilia is a dangerous pathogen that commonly causes nosocomial infections. Patients with compromised immune systems, chronic respiratory illnesses, and prior exposure to carbapenems are at higher risk. The complex virulence and resistance profile of this bacteria make treatment difficult due to limited antibiotics options and lack of data for dose optimization.
Article
Immunology
Alice J. Hsu, Patricia J. Simner, Yehudit Bergman, Amy J. Mathers, Pranita D. Tamma
Summary: In this article, we report a case of a 5-week-old infant with 8 days of S. maltophilia bacteremia while receiving TMP-SMX. Transitioning to cefiderocol monotherapy resulted in blood culture clearance within 24 hours, in the absence of any additional interventions. This is the first published case of the use of cefiderocol for a pediatric patient with an infection due to S. maltophilia. We review preclinical and clinical data that underscore why cefiderocol may be an effective treatment option for S. maltophilia infections.
OPEN FORUM INFECTIOUS DISEASES
(2023)
Article
Infectious Diseases
Jin Zhao, Yan Huang, Jian Li, Bo Zhang, Zhiwei Dong, Dong Wang
Summary: The study aimed to identify the optimal antibiotic combinations for sul-carrying S. maltophilia infections, and the results suggest that the combination of moxifloxacin and T/K can achieve a good in vitro bactericidal effect and prevent the emergence of resistance at clinical dosage regimens.
INFECTION AND DRUG RESISTANCE
(2022)
Article
Microbiology
Barbara Ellen Santos Carvalhais, Cristiana de Souza e Silva, Kenia Valeria dos Santos
Summary: The study evaluated the activity of different antimicrobials against Stenotrophomonas maltophilia biofilms at different stages, with surprising activity of gentamicin against the biofilms. Chloramphenicol and trimethoprim-sulfamethoxazole were indicated as good options for young biofilms, while trimethoprim-sulfamethoxazole and ceftazidime showed limited antibiofilm activity in mature biofilms.
FUTURE MICROBIOLOGY
(2021)